Raab presses ahead in D.C.

WASHINGTON - Genentech Inc. chief executive G. Kirk Raab last week launched his campaign to bring a distinct biotech perspective to the White House, and was to continue this week pressing the industry's case on drug pricing and technology transfer.

Raab held a series of high-level discussions with White House staff, Clinton administration members including members of the health care reform task force, and members of Congress in hopes of discouraging new pricing or technology licensing policies that would injure the biotechnology industry.